News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2022 Shelley Wood September 01, 2022
News Daily News New on the Scene Nonstatin Drugs: Experts Provide Guidance Caitlin E. Cox August 31, 2022
News Conference News ESC 2022 Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms Yael L. Maxwell August 31, 2022
News Conference News ESC 2022 DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark L.A. McKeown August 30, 2022
News Conference News ESC 2022 Smartphone App Can Detect AF, Influence Care: eBRAVE-AF Caitlin E. Cox August 30, 2022
Presentation ESC 2022 A Polypill Strategy in Secondary Prevention: Results of the SECURE Trial Presenter: Valentin Fuster August 29, 2022
News Conference News ESC 2022 P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER Todd Neale August 29, 2022
News Conference News ESC 2022 ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention Shelley Wood August 27, 2022
News Conference News ESC 2022 First Cardio-Oncology Guidelines From ESC Cover ‘Tremendous’ Territory L.A. McKeown August 26, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Daily News Enoxaparin Tops Aspirin for Preventing VTE After Hip or Knee Arthroplasty Todd Neale August 25, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Daily News Stroke, Bleeding Risks Key for Assessing Potential LAAO Benefit Todd Neale August 17, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Daily News CV Risk Factors, Disease Projected to Explode in Coming Decades L.A. McKeown August 01, 2022
News Daily News Myocarditis Phenotype Is a Key Predictor of Outcomes in COVID-19 Michael O'Riordan July 20, 2022
News Daily News ‘Code Blue’ for the Dire CVD Health Status of Most US Adults Michael O'Riordan July 05, 2022
News Daily News PFO Closure in Adults Over 60 Safe, but Patient Selection Key Yael L. Maxwell July 01, 2022
News Daily News Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients L.A. McKeown June 29, 2022